Receive The Newest Study Notifications

Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on unmet medical needs in immunology and oncology, announced today the start at the UPMC Hillman Cancer Center in Pittsburgh, PA of a new clinical study supported by Merck that will...

First Dual ICOS/CD28 Inhibitor to Enter Clinical Trials SEATTLE--(BUSINESS WIRE)-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other...

 Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-LF, a Phase 2b clinical trial evaluating emricasan, the company’s first-in-class, orally-active pan-caspase inhibitor. “With screening in the ENCORE-LF clinical trial...

ReGenTree, LLC (the Company), a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals, announced today that it has executed an agreement with Ora, Inc., located in Andover, Massachusetts, for the initiation of ARISE-3 to study the Company's new drug RGN-259...

46-page monograph describes scientific data supporting various uses of the French maritime pine bark extract The nonprofit American Botanical Council (ABC) has published an updated ingredient-specific monograph that summarizes selected scientific and clinical studies...

KIYATEC, Inc., today announced that Oregon Health & Science University (OHSU) Knight Cancer Institute has initiated patient enrollment into KIYATEC’s clinical study, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer...

Designs for Health commend this groundbreaking study from Denmark, which advances women’s health and offers hope for women everywhere A recent study conducted at Denmark’s Vejle Hospital, published in Pharmacological Research, provides evidence of delta-tocotrienol’s...

NIH-supported research aims to expand HIV prevention choices. WHAT A clinical trial has begun to examine the safety and use of two HIV prevention tools—oral pre-exposure prophylaxis (PrEP) and a vaginal ring—in adolescent girls and young women in southern Africa....

Strong interim survival trend (15.2 vs 8.5 months) emerging in IL4R positive patients Medicenna Therapeutics Corp.  ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company developing first-in-class Superkines and Empowered...

Phase 1 Clinical Trial to Evaluate AO-176 for the Treatment of Patients with Select Solid Tumors Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of next-generation anti-CD47 antibody therapies for cancer, today...

MBRX will now have three distinctive oncology drugs in clinic in four ongoing clinical trials WP1220, a STAT3 inhibitor, to begin clinical trials in Poland for the treatment of Cutaneous T-Cell Lymphona ("CTCL"), a rare and deadly skin cancer HOUSTON, Feb. 07, 2019...

Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced the upcoming presentation of additional analyses from the LOCATE clinical trial (NCT02680041). The LOCATE trial is a prospective, U.S., multicenter, open-label study investigating the...

Companies conducting clinical trials in the EU have been grappling with many questions regarding how to conduct a clinical trial that complies with the requirements of the GDPR. Two key questions have arisen: What is the legal basis for processing a participant’s...

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced the presentation of updated biomarker and clinical results from its two...

Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute walk test. Top-line Results Anticipated in H2...

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it had received an initial response from the U.S. Food and Drug Administration (FDA), Office of Tissue and Advanced Therapies division regarding the Company's submission of a proposed trial design for the...

Combination trial at UCLA Medical Center supported by demonstrated synergy and mechanistic rationale of targeted radiation from Actimab-A with venetoclax in preclinical studies Trial adds to Actimab-A and CLAG-M as Actinium's second targeted radiation combination to...

Biomerica Inc. (NASDAQ: BMRA) announced today regulatory and clinical advancements in its development program for its H. pylori diagnostic product. Based on recent discussions between Biomerica and the United States Food and Drug Administration (FDA) regarding the...

-- Open-label phase of study completed; primary end point results consistent¹ with prior reports (n=116) that showed 61% of patients with persistently active RA reported in the open-label period achieved low disease activity at 12 weeks -- -- Open-label phase results...

VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company's VLPM01 malaria vaccine. The Phase I/IIa clinical trial will begin recruiting participants...